Figure 2

Effect of drug on T cell activation. (A) HLA-A*02:01 donor #1 PBMCs and (B–D) HLA-A*11:01 donor #3 PBMCs were treated and assayed on day 7 as described in Fig. 1. Grey bars represent CD137 MFI in CD8⁺ tetramer positive T cells, red bars represent CD137 MFI in CD8⁺ tetramer negative T cells (bystander). ADO was omitted from donor #3 data due to low number of tetramer positive T cells. NLV, IVT, AVF and ATV represents NLVPMVATV, IVTDFSVIK, AVFDRKSDAK, and ATVQGQNLK, respectively. Data are representative of 4 (A) or 3 (B–D) independent experiments. Statistical analysis was performed as in Fig. 1 using median values of treated sample/peptide-only treated sample ratios (all comparisons within individual experiments). Log transformed median values were used in one-way ANOVA and subsequent Dunnett’s multiple comparison test relative to peptide-only treated samples. *adj p value ≤ 0.05; **adj p value ≤ 0.01; ***adj p value ≤ 0.001; ****adj p value ≤ 0.0001.